im waiting for some feedback on the series of court docs

New Post Public Reply Private Reply Replies (2) Message Board
thesmalls Goodspeed65 #4990
im waiting for some feedback on the series of court docs from a friend who is a business law attorney and try to get some direction one way or the other. right now - i think it is 50-50. on one side - KBM plays hardball as it doesnt want to have a big target painted on its back that it is an easy target to come after and have their entire model unravel.

on the flip side, the longer it draws out and more that becomes available, public opinion turns and brings intense scrutiny on the company and every investor/company that dealt with their seemingly usury practices starts to wonder if they can take a shot at them (not to mention more coming to light for SEC/Attorney generals who have "free" research being provided to them). in this regard, it behooves them to make a quick and advantageous settlement (to HJOE) with very strict NDAs to prevent them or other entities from "taking a chance". NDAs let the losing company (unless it is really a win-win) save face as they can put out their own PR anyway they want to with respect to resolving the dispute amicably and favorable to both parties (again - to discourage other suits).

one has to think to a small degree that the 13MM offer from NITE that keeps growing on the ASK is tied to this decision. there is no one at this point that would be holding that many shares that isnt in this for the long haul. at this point, vast majority of long term, large shareholders understand the waiting game, have bought into the filing delays, and understand the impact of this being settled or going to trial and further delays. if you were long with 13MM shares - you would have to have bought into the SMS model being real and growing, revenues increasing, and the company moving forward in parallel with the KBM trial. even if you WERE looking to liquidate and move on - why show your hand...?

so - what is NITE trying to accomplish by that enormous wall which is larger than most of the trading days in the past couple of months? why does it keep increasing? are they trying to systematic close short positions? accumulate for clients? etc?

i continue to buy. NITE had 10K at 14 and i put an order for 200K. it filled immediately and the 10K offer remained. next fill took it out and then the 13MM offer appeared at 15. i think when it comes down - this is going to move hard and fast and catch many former holders off guard as a lot of the float seems to be locked up long term. if this is settled, i have to imagine it will be cash only at best to KBM from HJOE (no shares) and the impetus will be provided for it to run. however, if more investors feel a settlement is reached, they will be adding speculatively ahead of any assumed announcement tryign to get in before the run. there will be a heavy mix of buying from long term holders and traders and the runs will be swift both up and down.

Hangover Joe's Holding Corporation (HJOE) Stock Research Links

HJOE Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 2

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Dorman Products: Anticipating Positive Earnings Ahead

Updated Category News Views 264

Optimistic Earnings Outlook for Dorman Products Dorman Products (NASDAQ: DORM) is gearing up to announce its quarterly earnings report soon, generating buzz among investors. The anticipated release date is approaching, and many are keen to see how the company performs. Expectations Surrounding EPS Analysts have set expectations high, forecasting an earnings per share...

Continue Reading
Fission Uranium Corp. Publishes Results from Special Meeting

Updated Category News Views 53

Fission Uranium Corp. Shares Results from Special Meeting Fission Uranium Corp. (TSX: FCU, OTCQX: FCUUF) recently conducted an important meeting with its securityholders. During this special meeting, the company revealed the results of key votes that will shape its future direction and partnership strategies. Shareholders Express Strong Support for Key Resolutions At the...

Continue Reading
Prevounce Health Enhances Integration with Elation Health's EHR

Updated Category News Views 173

Prevounce Health Partners with Elation Health for Enhanced Care The integration between the Prevounce remote care management platform and the Elation electronic health record (EHR) system marks a significant advancement in healthcare technology. This partnership aims to streamline healthcare processes and enhance patient care through technological synergy. Understanding...

Continue Reading
Exploring the Expanding Landscape of Social Media Listening

Updated Category News Views 196

Growing Demand for Social Media Listening The social media listening market is experiencing remarkable growth, expected to surge from USD 8.36 billion in 2023 to USD 27.63 billion by the year 2032. This projection represents a compound annual growth rate (CAGR) of approximately 14.27% during the forecast period. The increasing need for real-time insights into consumer...

Continue Reading
Orthopedic Braces Market Set to Surge to $5.5 Billion by 2030

Updated Category News Views 123

Overview of the Orthopedic Braces and Supports Market The global orthopedic braces and supports market is currently experiencing significant growth, with a valuation of approximately US$3.8 billion in 2024. This market is expected to reach US$5.5 billion by 2030, showcasing a compound annual growth rate (CAGR) of 6.5% across this period. One of the primary factors...

Continue Reading